Cyclin-dependent kinase 9 – Positive transcription elongation factor b complex (CDK9/P-TEFb)

The Cyclin-dependent kinase 9 (CDK9) – Positive transcription elongation factor b (P-TEFb) complex is a critical regulator of eukaryotic gene expression, primarily responsible for the transition of RNA polymerase II from promoter-proximal pausing to productive elongation (PMID: 29038457). The complex is composed of the catalytic subunit CDK9 and a regulatory cyclin partner, such as Cyclin T1, T2, or K (UniProt P50750). P-TEFb functions by phosphorylating the C-terminal domain (CTD) of RNA polymerase II at Serine 2, as well as negative elongation factors like DSIF and NELF, which allows for the synthesis of mature mRNA (PMID: 30104663). In many cancers, P-TEFb is hyperactivated, driving the expression of short-lived anti-apoptotic proteins like MCL-1 and oncogenes like MYC, which are essential for tumor cell survival (PMID: 24513173). Additionally, the complex is a known host factor for HIV-1, where the viral Tat protein recruits P-TEFb to the viral promoter to stimulate transcription (PMID: 11850627). Therapeutic strategies focus on small-molecule inhibitors that target the ATP-binding pocket of CDK9 to selectively downregulate these oncogenic drivers, though managing systemic toxicity remains a significant clinical challenge (PMID: 32817124). Clinical development of these inhibitors has shown promise in treating hematologic malignancies, where rapid depletion of MCL-1 can induce apoptosis in tumor cells (PMID: 29038457). Overall, the CDK9/P-TEFb complex represents a pivotal node in transcriptional regulation with significant implications for oncology and virology.

Other names

P-TEFbCDK9-Cyclin T complexC-terminal domain kinaseCTD kinaseCDK9-CCNT1 complex

Inhibition of CDK9 kinase activity within the P-TEFb complex, preventing phosphorylation of RNA polymerase II C-terminal domain (CTD) at Serine 2, thereby blocking transcriptional elongation of short-lived pro-survival and oncogenic proteins (PMID: 32817124).